MK3543-017

A Multicenter, Open-Label, Extension Study Evaluating the Safety and Efficacy of Bomedemstat for the Treatment of Participants Enrolled in a Prior Bomedemstat Clinical Study

Contatti: Monia Marchetti, monia.marchetti@uniupo.it

Trattamento: Bomedemstat

Sindromi MIELOPROLIFERATIVE CRONICHE target: Essential Thrombocythemia – Myelofibrosis

Principali Criteri Inclusione:

1. Participant is from a bomedemstat study sponsored by Imago Biosciences, Inc. (a subsidiary of Merck & Co., Inc.) or MSD (feeder study) established by the Sponsor as MK-3543-017 ready.

2. Participants from the IMG-7289-202/MK-3543-005 study must have received at least 6 months of treatment with bomedemstat, must be safely tolerating bomedemstat, and must be receiving clinical benefit from its use in the estimation of the investigator.

3. ET and PV participants from established feeder studies other than IMG-7289-202/MK-3543-005 must have achieved confirmed hematologic remission, must be safely tolerating bomedemstat, and must be receiving clinical benefit from its use in the estimation of the investigator.